Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering (Dipanjan Pan)
Prof. Pan joined University of Illinois in fall 2013. Previously, He was an Assistant Professor of Medicine, Research at the Division of Cardiology, Washington University in St. Louis. He also...
By: NanoBio Node
Read the original post:
Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering (Dipanjan Pan) - Video
The new report by Expert Market Research titled, GlobalBusiness Jets MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global business jets market, assessing the market based on its segments like aircraft type, end use, systems, services, platform and major regions like North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.
Request a free sample copy in PDF or view the report [emailprotected]https://www.expertmarketresearch.com/reports/business-jets-market/requestsample
The key highlights of the report include:
Market Overview (2016-2026)
The market for business jets has seen substantial growth due to factors such as the increasing number of staff and the introduction of fresh aircraft programs. Also, increased knowledge across different segments offers an enormous market opportunity for key players in the business jets market. The light aircraft segment is expected to grow at the fastest rate during the forecast period. The expansion of the light aircraft segment can be attributed to its growing use as business jets for inter- and intra-city transportation, as well as greater brand marketing by manufacturers. The sector is expected to grow even more as technology advances and the middle-class population grows. The business jet industry is expected to grow as air mobility improves in both developed and developing countries.
Industry Definition and Major Segments
A private jet, often known as a business jet or bizjet, is a jet aircraft designed to transport small groups of people. Business jets can be customised for specific missions, such as casualty evacuation or parcel delivery, and some are used by public bodies, government officials, and the military services.
Explore the full report with the table of [emailprotected]https://www.expertmarketresearch.com/reports/business-jets-market
Based on the aircraft type, the industry is divided into:
Based on the end use, the industry is divided into:
Based on the system, the industry is divided into:
Based on the services, the industry is divided into:
Based on the platform, the industry is divided into:
The regional markets for business jets include:
Market Trends
Geographically, North America currently holds the largest market share and is likely to maintain that position throughout the forecast period. The region has the worlds largest operational business jet fleet, with the United States accounting for most of them. Most of the demand is for light and large jets due to the presence of numerous high-net-worth people and corporate companies. In addition, there has been a rise in demand for charter services in the region during the last few years. In 2020, demand for business aviation has increased as a result of COVID-19s influence on commercial aviation. Even though overall flight activity decreased in 2020, business aviation flight activity began to recover steadily in May of that year. Furthermore, following the lifting of COVID-19 pandemic restrictions in the region in 2021, corporate jet activity began to surge. In addition, charter companies have reduced their pricing to accommodate the business jet prospects. The expansion of charter operations in the region has prompted charter operators to embark on fleet modernization plans in order to improve fleet efficiency.
Key Market Players
The major players in the market are APG-Neuros, Safran S.A. (SAF (EPA)), Curtiss-Wright Corporation (CW (NYSE)), Esterline Technologies Corporation, Meggitt PLC (MGGT (LON)), United Technologies Corporation (UTX (NYSE)), Eaton Corporation Inc (ETN (NYSE)), Ametek, Inc. (AME (NYSE)), among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Read More Reports:
Global Collagen Market:https://www.expertmarketresearch.com/reports/collagen-market
Global Biologics Market:https://www.expertmarketresearch.com/reports/biologics-market
Global Metamaterial Market:https://www.expertmarketresearch.com/reports/metamaterial-market
Global Nanomedicine Market:https://www.expertmarketresearch.com/reports/nanomedicine-market
About Us:
Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.
At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.
We also provide state-of-the-art procurement intelligence through our platform,https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.
Informes de Expertos (https://www.informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.
Determined to bring client satisfaction, we make sure that our tailored approach meets the clients unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.
Media Contact
Company Name: EMR Inc.Contact Person: Steven Luke, Corporate Sales Specialist U.S.A.Email:[emailprotected]Toll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite:https://www.expertmarketresearch.com
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
How to introduce Nanomedicine Products and bring their Impact to the Market?
Speaker: Dr. Christopher R. Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation Pasadena, CA (USA) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.
By: TAUVOD
Go here to see the original:
How to introduce Nanomedicine Products and bring their Impact to the Market? - Video
Panel - Nanomedicine and Targeted Drug Delivery
CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.
By: TAUVOD
See the article here:
Panel - Nanomedicine and Targeted Drug Delivery - Video
ProfessorTimo Laaksonen, who divides his time between the University of Helsinki and Tampere University, has received a grant of roughly 2 million from the European Research Council (ERC). Laaksonens research focuses on releasing pharmaceutical agents in a controlled way in the body using blue or ultraviolet light.
Employing light in drug release is not a new invention as such. With the help of red light, for instance, the membrane of a liposome transporting a nano-sized drug can be made more permeable, releasing the drug. However, blue light provides a more extensive set of tools compared to red light.
Blue and UV light have more energy, powerful enough, for example, to break up chemical bonds in a certain type of drug carrier and detach the drug molecules bound to the carriers surface, Laaksonen explains.
Earlier, the use of UV light has been hindered by the fact that, even at its best, it travels less than a hundred micrometres in the tissue, or the breadth of a single average hair. Red light advances much further. That UV light can damage the body adds another complication, while red light is markedly safer.
Laaksonen is now focusing on how to safely target blue or UV light to the site where the drug should be released. There are two options: either photons could be locally upconverted to a higher energy level inside the body, or a variety of drug implants activated by light could be used.
In practice, photoactivation could potentially be used to release drugs, for example, at the precise moment when another dose is needed. It could be a certain time every morning, or we could continually adjust the release rate to suit the patient.
Timo Laaksonen heads research groups at both the Faculty of Pharmacy, University of Helsinki and the Faculty of Engineering and Natural Sciences, Tampere University. The pharmacy component of the project is carried out in Helsinki and the photochemical component in Tampere. The University of Helsinki will receive 60% of the ERC grant and Tampere University 40%.
Go here to see the original:
Significant EU funding awarded to nanomedicine research Blue light used to release pharmaceutical agents at the target - India Education Diary
The International Space Station (ISS) is a unique laboratory available to mankind. The micro-environment, the extreme conditions, and the demanding requirements of space make it an excellent test field for new ideas and devices. Reaching the ISS laboratory this Monday is a next-generation implantable drug delivery system that can be operated remotely and could be used to treat and even prevent chronic ailments back on Earth.
The system is one of the many science experiments that were launched on theCommercial Resupply Services 23 (CRS-23), undertaken by SpaceX and NASA. The third mission for SpaceX, under an agreement, where privately operated spacecraft transport cargo and supplies to the ISS, used the Cargo Dragon 2 capsule, and reused a Falcon 9 booster, NASA said in a press release.
Considered insignificant and irrelevant to human existence just a couple of decades ago, experiments on the ISS are now looked at as a gateway to the science of the future. As colonization of planets comes closer to reality, it is pertinent to know the impact of space travel on humans and also if materials known on Earth retain their properties in different environments. More than 3,000 experiments have been carried out onboard the ISS so far, Nature reportedlast year.
Joining the list is the remotely controlled implantable drug delivery system, developed by Professor of Nanomedicine,Alessandro Grattoni, and his team at the Houston Methodist Research Institute. The purpose of the implantable drug delivery systems is to deliver precise quantities of medication only to target delivery sites in the body. While previous iterations have used specialized membranes to do this passively, Grattoni and his team have now developed an active system that can be controlled remotely using an app.
Faraday Research Facility (FRF), a multi-purpose research facility that is designed to connect with the ISS, houses the system. Inside the FRF are smaller chambers that can hold different experiments in place to be conducted in space. Developed byProXopS, LLC, the FRF can hold up to 12 research environments in place and can be operated from the ground using the ISS Wi-Fi.
Grattoni's trial system consists of sealed containers of saline tubes that will be operated from the ground. If successful, a future flight will use this system to deliver drug doses in rodent subjects, enabling complex drug dose regimens without stressing the subjects, the press release said. Apart from using the system for telemedicine back on Earth, it might also be utilized in astronauts who are on long-duration space missions and for diseases such ashypertension, rheumatoid arthritis, and sleep disorders.
Also on board the FRF is an experiment from the Girl Scouts who have sent ants to see how they colonize in low-gravity environments.
Onboard the cargo that will dock on Monday is a robotic arm from GITAI Japan to the feasibility of using robots to do routine and hazardous tasks in orbit. The technology could also be applied for disaster relief and servicing of nuclear power plants, back on Earth, said a NASA press release.
Astronauts on the ISS will also use a device that will attach to their iPad and take images of their retina. This is expected to improve our understanding ofSpace-Associated Neuro-Ocular Syndrome (SANS), seen in two-third of the astronauts, who have spent a month or longer in space.
Go here to see the original:
SpaceX Takes Remotely Controlled Drug Delivery System to the ISS - Interesting Engineering
The global nanomedical market was valued at $134.4 billion in 2016. This market is projected to grow at a compound annual growth rate (CAGR) of 14.0% from 2017-2022, and should reach $293.1 billion by 2022 from $151.9 billion in 2017.
Report Scope:
This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.
Click Here to Get Sample Premium Report @ https://www.trendsmarketresearch.com/report/sample/12261
Report Includes:
An overview of the global markets for nanotechnology used in medical applications Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022 A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market
Summary
Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.
The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.
Reasons for Doing the Study
Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.
More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/12261
Tel Aviv University researchers use tiny molecular scissors to target aggressive metastatic cancer cells
Israeli scientists have developed a cutting-edge nanotechnology system that can destroy cancerous cells in mice.
The Tel Aviv University team of researchers pioneered a treatment method that is so precise, it is almost as if tiny molecular scissors were being used to kill the cancer.
We developed a delivery system for these molecular scissors that can specifically reach tumor cells while leaving normal cells intact, Dr. Daniel Rosenblum, a postdoctoral fellow from the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University, told The Media Line.
By cutting their DNA in specific genes that are responsible for cell division or cell survival, we basically neutralize them and they die from the treatment, he said. The system we developed is based on the Cas9 CRISPR protein in a [messenger] RNA format.
The process, known as CRISPR genome editing, allows researchers to alter DNA sequences. Specifically, scientists at the university created what is known as CRISPR-LNPs, a lipid nanoparticle delivery system that carries a genetic messenger (known as messenger RNA), along with a navigation system that can recognize cancerous cells.
The findings of the peer-reviewed research were published last month in the Science Advances journal.
This is the first study in the world to prove that the CRISPR genome editing system can be used to treat cancer in a living animal effectively,said Prof. Dan Peer, vice president for Research and Development at Tel Aviv University and head of TAUs Laboratory of Precision NanoMedicine.
The idea there is to take the cells from the patients, edit them in a plate outside the body and then inject them back into the patient, he told The Media Line. We believe that this could be expanded to much more than just the two models that we have tried.
So far, researchers at Tel Aviv University have tested the technology on mice and have observed no adverse reactions. This stands in contrast to chemotherapy, which kills both cancerous and healthy cells.
The CRISPR-LNPs were tested on glioblastoma tumors, an extremely aggressive type of brain cancer that has a five-year survival rate of only 3%. In addition, the researchers tested the system on metastatic ovarian cancer, a major cause of death among women and the most lethal cancer in the female reproductive system.
Wake up to the Trusted Mideast News source Mideast Daily News Email
For the glioblastoma tumors, the treatment was found to double the average life expectancy of mice and improve their overall survival rate by about 30%. For ovarian cancer, the overall survival rate rose by a whopping 80%.
When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried
We envision that we can simply inject [the treatment] into the body and because of the GPS they can find their way to the tumor, Anna Gutkin, a doctoral student in the laboratory, told The Media Line. We encountered several hurdles in the development of this technology but its exciting to work on this. It really opens new avenues for us to develop novel therapies.
Aside from its potentially revolutionary impact on future cancer treatments, the technology also opens the door for treating rare genetic diseases and viral diseases such as AIDS, according to the researchers. A similar technology based on messenger RNA currently is being used by Pfizer (BioNTech) and Moderna for their COVID-19 vaccines.
Our system is a bit more sophisticated both from the materials they are created from [and] we also gave it a GPS system, which is pretty unique, Rosenblum noted.
In the future, Peer and his team hope to test the groundbreaking technology on larger animal models. Human trials are expected to begin in about two years.
Because of the coronavirus crisis we have witnessed how fast new approaches could be translated into the clinic, Peer said.
When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried, he concluded.
The rest is here:
Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) - The Media Line
Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.
Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.
REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223
The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.
The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.
Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.
Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.
DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223
Scope of the Nanomedicine Market:
Nanomedicine Market by Modality:
Diagnostics TreatmentsNanomedicine Market by Diseases:
Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:
Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:
Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:
Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.
MAJOR TOC OF THE REPORT
Chapter One: Nanomedicine Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Nanomedicine Market Competition, by Players
Chapter Four: Global Nanomedicine Market Size by Regions
Chapter Five: North America Nanomedicine Revenue by Countries
Chapter Six: Europe Nanomedicine Revenue by Countries
Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries
Chapter Eight: South America Nanomedicine Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries
Chapter Ten: Global Nanomedicine Market Segment by Type
Chapter Eleven: Global Nanomedicine Market Segment by Application
Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)
Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/
About Us:
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Vikas Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: sales@maximizemarketresearch.com
Contact: +919607065656/ +919607195908
Website:www.maximizemarketresearch.com
Read the original:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and... - Azizsalon News
: New York, United States, 31-July-2020, (Via WiredRelease), (Reports and Data) The global nanomedicine market is expected to reach USD 343.8 billion by 2026, according to a new report by Reports and Data. Increased global incidence of cancer coupled with growing prevalence of cardiovascular diseases is likely to be the key factors governing market growth. Based on the WHO statistics, in 2018 around 18.07million new cases were registered for cancer in 2018. Additionally, cancer accounted for around 9.5 million deaths in 2018. The incidence of cancer was significantly high and lied around 48.4 percent in Asia Pacific.
Nanomedicine is being increasingly adopted for the treatment of various diseases including cancer and cardiovascular disease. Apart from improved efficacy and safety, factors such as bio-availability and ability to deliver diagnostic and therapeutic agents to targeted sites are expected to stimulate market growth.
Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.reportsanddata.com/sample-enquiry-form/1048
The COVID-19 impact: Covid-19s spread has affected manufacturing and construction activities worldwide. Logistic limitations and reconsiderations of the raw material requirements are becoming a problem for producers. The producers have relied on derived demand as an intermediate commodity to rationalize production. The pandemics economic impact on companies and financial markets is also not favorable. Stock market volatility and decreasing global growth are anticipated, which will affect the market. The market has experienced a downturn over the weeks, which may continue over the next few months. The Asia Pacific is the most affected region by this pandemic, with China at the center of the outbreak. Most initiatives in multiple countries have changed to a temporary halt. Development, as well as supply, is put on hold, creating losses for suppliers, dealers and customers alike.
Key participants include
Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation and Johnson & Johnson.
Get Discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048
For the purpose of this report, Reports and Data have segmented into the global Nanomedicine market on the basis of type, propellants, application, and region:
For the purpose of this report, Reports and Data have segmented global Nanomedicine Market on the basis of products, drug delivery system, application and region:
Product Outlook (Revenue, USD Billion,2018-2026)TherapeuticsRegenerative MedicineIn-vitro diagnosticsIn-vivo diagnosticVaccines
Drug Delivery System Outlook (Revenue, USD Billion, 2018-2026)NanobotsNanoghostsNanoclustersNanobubblesExosomesInjectable Nanoparticle GeneratorDendrimersLiposomesCarbon nanotubeGrapheneOthersApplicationOutlook (Revenue, USD Million, 2015-2026)OncologyInfectious diseasesCardiologyOrthopedicsOthers
Regional Outlook (Revenue, USD Million; 2017-2027)
North America
U.S
Europe
U.K
France
Asia Pacific
China
India
Japan
MEA
Latin America
Brazil
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/nanomedicine-market
Key aspects of the Nanomedicine Market Report:
The report comprises of Nanomedicine market overview, market share, demand and supply ratio, supply chain analysis, and import/export details.
The report explores different strategies and procedures undertaken by key market players that assist in making profitable decisions.
The report covers all the crucial information about the products and services of major competitors.
About Us: Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development.
Contact Us: John WatsonHead of Business DevelopmentReports and Data | Web: http://www.reportsanddata.comDirect Line: +1-212-710-1370 E-mail: sales@reportsanddata.com
This content has been published by MARKETYSERS GLOBAL CONSULTING LLP company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.
Read more:
Nanomedicine Market To Reach USD 343.8 Billion By 2026 | CAGR of 12.6% (1) - PharmiWeb.com
UK based MR Solutions presented a simultaneous 7T PET/MRI preclinical imaging system optimized for nanoparticle imaging to the first joint annual congress of the French Nanomedicine Society (SFNano), and the French national Competency Cluster in Nanoscience CNano which was held in Dijon in early December.
Nanoparticles (NPs) have demonstrated great potential in diagnostic medicine particularly as contrast agents using MRI scanners. Iron oxide, gold, and gadolinium NPs have been used in preclinical and clinical studies as contrast enhancing agents.
The participants at the SFNano CNano 2019 joint meeting work in the scientific areas of nanomedicine, nanotechnology and nanoscience. MR Solutions presented the technology in a talk to the scientific community and displayed the PET/MRI system at the accompanying exhibition.
MR Solutions 7T PET/MR preclinical imaging system uses dry magnet, or liquid-helium free technology facilitating a compact system for multi-modality imaging. Researchers are able to combine high resolution MRI data with the high sensitivity of PET data for anatomical and quantitative studies.
Fabrice Chaumard, MR Solutions sales and marketing director commented: We were delighted that there was so much interest from the scientific community in our preclinical PET/MRI systems for nanoparticle imaging. This system provides much better imaging data and at a fraction of the cost of two separate systems.
The PET capability is provided by solid state detectors which are incorporated in the bore of the MRI scanner. The scanner combines the exquisite structural and functional characterisation of tissue provided by MRI with the extreme sensitivity of PET imaging for metabolism and tracking of uniquely labelled cell types or cell receptors. This is particularly useful in oncology, cardiology, and neurology research.
MR Solutions is the worlds leading independent developer and manufacturer of preclinical multi-modality MRI technology and remains the only company to deliver a commercial cryogen-free 3T to 9.4T range of compact MRI scanners. In recognition of the companys innovation and business acumen the company has received three Queens Awards for Enterprise for innovation in 2016 and 2019 and for international trade in 2017.
MR Solutions has over 30 years experience and in excess of 2000 installations across the world. This includes sales of their MRI spectrometers. Its scanners are renowned for their excellence in terms of superior soft tissue contrast and molecular imaging ability.
< Ends
Visit link:
MR Solutions participates in the first nanomedicine joint annual meeting in Dijon - BioSpace
The unfolding Sars-2-CoV outbreak is laying bare the worlds need for effective antivirals. According to University of Lille chemist Sabine Szunerits, we should invest in this now, knowing that viruses will be an issue in the 21st century. With this in mind she and collaborators at the Pasteur Institute in Lille, France have, over the past few years, been developing a new approach to tackling viruses including coronaviruses that takes advantage of the unique properties of nanoparticles.
There are only a handful of approved antiviral treatments and these are only effective against a few specific viruses. This means that when new viral diseases like Covid-19 emerge doctors are left trying to repurpose existing antivirals in the hope that they will have an effect on the new disease.
Viruses are not technically alive, they are packages of RNA or DNA that can only replicate by hijacking its hosts genetic machinery. Antivirals do not destroy these packages, they are small molecules designed to block viral replication, thereby reducing symptoms and infectivity while the immune system deals with them. Unfortunately, because viruses rely on the hosts DNA replication machinery finding drugs that only target and bind specific virus proteins and not those of the host cell is a challenge. This lack of specificity means large doses of antivirals are often needed to achieve the desired effect, which in turn increases toxicity.
The field of nanomedicine, however, has been exploring how nanoparticles can overcome some of these problems. The promise of nanoparticle antivirals comes from their multivalency the number of interactions occurring as molecules bind together. The nanoparticle of choice for Szunerits are carbon quantum dots (CQDs) which are spherical, have a high surface-to-volume ratio and are smaller in size than viruses creating conditions where multivalent interactions can play a role. The surface of the CQDs can also be coated with molecules that bind the proteins viruses use to enter cells. The spherical shape and smaller size of the CQD mean these molecules can form extremely tight multivalent bonds with proteins all over the viruss surface, blocking it from attaching to and infecting a host cell. Szunerits and team started this work in 2018, testing the ability of CQDs with boronic acid groups to reduce the infectivity of a mild strain of human coronaviruses in cell lines.They achieved significant reductions in viral entry relative to controls and are now working on CQDs coated with Middle East Respiratory Syndrome (MERS) specific peptides, showing that CQDs should be able to be adapted to specific viral threats.
Cameron Alexander at the University of Nottingham, who works with nanoparticle-based RNA vaccines sees the potential adaptability of this type approach. Once youve got a nanoparticle with the right spacing and chemical functionalities to match one virus, its not inconceivable to think how you could plug and play different groups on that surface to find another virus.
Igor Medintz, a senior scientist with the US Naval Research Laboratory in Washington DC, agrees that the plug and play nature of this approach is promising because, as long as a molecule is biocompatible, there are few limitations to the options available. Theres a huge library of non-natural amino acids that can be accessed as well you can synthesise peptides with just about any chemical or functional group possible and those could give them very high binding affinity beyond the naturally occurring ones, he says.
Another drawback of current antivirals is that they are often insoluble making administering them more difficult. Often drugs on the market are rather hydrophobic and the pharma industry always likes delivering drugs orally, says Szunerits. Nanoparticles like CQDs are hydrophilic, however, allowing them to circulate better. Due to their size, they are also easier to deliver as a fine spray, which for infections that affect the lungs, such as coronaviruses, would be more effective.
Right now, Szunerits and the team are experimenting with liposome packages to deliver CQDs, as well as assessing the big question of how the body will handle them once theyve serve their function. Early studies by her group have shown that CQDs injected into mice are passed in urine, which along with in vitro toxicity studies provide hopeful signs that the body can tolerate them.
As with any new treatment moving from the lab to clinical trials and then scaling-up production is a long road. According to Alexander, making these types of particles is easy enough but ensuring uniformity in large batches required for a therapeutic becomes problematic. When youre making some of these systems, you need to check that the size is correct, the functionality is correct and the more functionality you put in it, the more complicated they are to characterise, he says. The more complicated to characterise, the harder it is to get regulatory approval, and the harder it is to manufacture.
Back to Browse Journals International Journal of Nanomedicine Volume 12
Di Wu, Mengjie Si, Hui-Yi Xue, Ho-Lun Wong
Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA
Abstract: Breast cancer is the most common malignant disease in women worldwide, but the current drug therapy is far from optimal as indicated by the high death rate of breast cancer patients. Nanomedicine is a promising alternative for breast cancer treatment. Nanomedicine products such as Doxil and Abraxane have already been extensively used for breast cancer adjuvant therapy with favorable clinical outcomes. However, these products were originally designed for generic anticancer purpose and not specifically for breast cancer treatment. With better understanding of the molecular biology of breast cancer, a number of novel promising nanotherapeutic strategies and devices have been developed in recent years. In this review, we will first give an overview of the current breast cancer treatment and the updated status of nanomedicine use in clinical setting, then discuss the latest important trends in designing breast cancer nanomedicine, including passive and active cancer cell targeting, breast cancer stem cell targeting, tumor microenvironment-based nanotherapy and combination nanotherapy of drug-resistant breast cancer. Researchers may get insight from these strategies to design and develop nanomedicine that is more tailored for breast cancer to achieve further improvements in cancer specificity, antitumorigenic effect, antimetastasis effect and drug resistance reversal effect.Keywords: nanomedicine, breast cancer, targeted delivery, drug therapy, drug resistance, tumor microenvironment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Michelle Bradbury MD, PhD, who is a Professor of Radiology, Director of Intraoperative Imaging, and Co-Director of an National Cancer Institute awarded Nanomedicine Center (MSK-Cornell Center for Translation of Cancer Nanomedicines), has been named a 2017 Top Doctor in New York City, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care.
Dr. Michelle S. Bradbury is a highly experienced physician who has been in practice for over two decades. Her career in medicine started in 1997, when she graduated from the George Washington University School of Medicine and Health Sciences in Washington, D.C. An internship, residency and then fellowship followed, all completed at Wake Forest University in Winston-Salem, North Carolina. Dr. Bradbury also holds a Doctor of Philosophy Degree from the Massachusetts Institute of Technology.
Dr. Bradbury is certified by the American Board of Radiology in both Diagnostic Radiology and Neuroradiology. She is particularly renowned, however, as a leading expert in nanomedicine and in neuroradiology, using CT and MRI imaging of the brain, neck and spine to diagnose conditions of the nervous system. Alongside her work in this field she has been at the forefront of nanomedicine research and clinical trials.
Dr. Bradbury keeps up to date with the latest advances in her field through her active membership of professional organizations including the American College of Radiology, the World Molecular Imaging Congress, and the American Society of Nanomedicine. Her expertise and dedication makes Dr. Michelle S. Bradbury a very deserving winner of a 2017 Top Doctor Award.
About Top Doctor Awards
Top Doctor Awards specializes in recognizing and commemorating the achievements of todays most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors
See the original post here:
Expert Radiologist and Clinician Scientist, Michelle S. Bradbury, MD, PhD, is to be Recognized as a 2017 Top Doctor ... - PR NewsChannel (press...
Global Nanomedicine Market Research Report 2017 to 2022 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Nanomedicine Market.
Companies Mentioned are GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A.
Primary sources are mainly industry experts from core and related industries, and suppliers, manufacturers, distributors, service providers, and organizations related to all segments of the industrys supply chain. The bottom-up approach was used to estimate the global market size of Nanomedicine based on end-use industry and region, in terms of value. With the data triangulation procedure and validation of data through primary interviews, the exact values of the overall parent market, and individual market sizes were determined and confirmed in this study.
Sample/Inquire at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017/inquiry
This report segments the global Nanomedicine market on the basis of types Regenerative Medicine, In-vitro & In-vivo Diagnostics, Vaccines, Drug Delivery. On the basis of application Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology.
Essential points covered in Global Nanomedicine Market 2017 Research are:-
This independent 116 page report guarantees you will remain better informed than your competition. With over 170 tables and figures examining the Nanomedicine market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2022.
The global Nanomedicine market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.
Browse Full Report at: https://www.marketinsightsreports.com/reports/08308548/global-nanomedicine-market-research-report-2017
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Storage Area Network Switch in these regions, from 2012 to 2022 (forecast), covering
by Regions
The report provides a basic overview of the Nanomedicine industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.
Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. Whats more, the Nanomedicine industry development trends and marketing channels are analyzed.
The research includes historic data from 2012 to 2016 and forecasts until 2022 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Nanomedicine on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Nanomedicine Market and assist manufacturers and investment organization to better grasp the development course of Nanomedicine Market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
There are 15 Chapters to deeply display the global Nanomedicine market.
Chapter 1, to describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Nanomedicine, with sales, revenue, and price of Nanomedicine, in 2016and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Nanomedicine, for each region, from 2012to 2017;
Chapter 5, 6, 7,8and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;
Chapter 10and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;
Chapter 12, Nanomedicine market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;
Chapter 13, 14 and 15, to describe Nanomedicine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.
Original post:
Nanomedicine Market Growth Opportunities for Distributers 2017 - Equity Insider (press release)
Killer T cells surround a cancer cell. Credit: NIH
Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.
The strategy involves using lipid polymer based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor initiating cells (BTICs).
"BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy," explained the study's first author, Dr. Dou Yu, research assistant professor of neurological surgery at Northwestern University Feinberg School of Medicine.
The findings were published in the journal Proceedings of the National Academy of Sciences.
Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA)short sequences of RNA molecules that reduce the expression of specific cancer promoting proteinsdirectly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.
"This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind," said Yu, who collaborated on the research with principal investigator Dr. Maciej Lesniak, Michael J. Marchese Professor of Neurosurgery and chair of neurological surgery.
Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patient's tumor.
In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissuesbut not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.
"This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling," Yu said. "Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits."
The strategy could also apply to other medical conditions related to the central nervous systemnot just brain tumors.
"Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform," Yu said.
Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.
"Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer," Lesniak summed up.
Explore further: Cold virus, stem cells tested to destroy deadly brain cancer
More information: Dou Yu et al, Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1701911114
The rest is here:
Nanomedicine opens door to precision medicine for brain tumors - Phys.Org
Nanomedicine RA with Dr. Bottini
Dr. Massimo Bottini, a researcher and bio-engineer who splits his time between the University of Rome and the Sanford Burnham Medical Research Institute in S...
By: Arthritis National Research Foundation
The worldwide Nanomedicine Market report is an in-depth research on the current situation of the Nanomedicine industry. The research study of Global Nanomedicine Market 2017 offers a strategic assessment of Nanomedicine market. The industry report focuses on the growth opportunities, which will help the Nanomedicine industry to expand operations in the existing markets globally.
Firstly, Nanomedicine Market report introduces a basic overview of the Nanomedicine industry, which includes Nanomedicine definitions, applications, classifications and Nanomedicine industry chain structure. Worldwide Nanomedicine market analysis is provided for the international market including Nanomedicine industry competitive analysis, Nanomedicine market development history and major sectors development status on Nanomedicine industry scenario.
Get Sample Report Here: https://market.biz/report/global-nanomedicine-market-2017/61375/#inquiry
Global Nanomedicine Market 2017: Competitive Landscape and Key Vendors
1 GE Healthcare 2 Johnson & Johnson 3 Mallinckrodt plc 4 Merck & Co. Inc. 5 Nanosphere Inc. 6 Pfizer Inc. 7 Sigma-Tau Pharmaceuticals Inc. 8 Smith & Nephew PLC 9 Stryker Corp 10 Teva Pharmaceutical Industries Ltd. 11 UCB (Union chimique belge)
Nanomedicine Market 2017: Type Segment Analysis
Regenerative Medicine In-vitro & In-vivo Diagnostics Vaccines Drug Delivery
Nanomedicine Market 2017: Applications Segment Analysis
Clinical Cardiology Urology Genetics Orthopedics Ophthalmology
The Nanomedicine market covers the geological regions including US, EU, China, and Japan. Other regions can also be added efficiently as per customers need. The report also displays the market size for each category during the forecasting period from 2017 to 2022.
Further, the report guides the client according to the various aspects of Nanomedicine industry like supply chain analysis, Nanomedicine industry rules, and policies, along with product cost, product images, the cost structure, import/export information and utilisation figures. The detailed competitive plan of Nanomedicine industry report will help the clients to systematically specify better business strategies for a desired business payoff.
To Purchase Complete Report Click Here: https://market.biz/report/global-nanomedicine-market-2017/61375/
At the end, report Global Nanomedicine Market 2017 focuses the feasibility of new investment projects is assessed, and overall research conclusions are offered on Nanomedicine market scenario.
Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15th of July in Boston, MA. Following the success of last years inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Societys Annual Meeting and Exposition from the 16th to 18th of July.
The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address To target or not to target: lessons from RNAi-based targeted lipid nanoparticles being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.
The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich as well as providing networking opportunities throughout the day.
The rest is here:
Precision NanoSystems to Host Nanomedicines Symposium - Technology Networks
Insights on the Global Healthcare Nanotechnology (Nanomedicine) Market
PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.
As per the report, the global Healthcare Nanotechnology (Nanomedicine) market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Healthcare Nanotechnology (Nanomedicine) market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)
Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370
Critical doubts related to the Healthcare Nanotechnology (Nanomedicine) market addressed in the report:
Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370
Segmentation of the Healthcare Nanotechnology (Nanomedicine) market
The report bifurcates the Healthcare Nanotechnology (Nanomedicine) market into different segments to provide a clear understanding of the various aspects of the market.
Regional Outlook
The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Healthcare Nanotechnology (Nanomedicine) market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Healthcare Nanotechnology (Nanomedicine) market.
Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.
Key geographies evaluated in this report are:
Key features of this report
For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370
Important insights present in the report:
See more here:
Healthcare Nanotechnology (Nanomedicine) Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2015 2021 - Jewish Life News